Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.7 EUR | -1.21% | -1.21% | -14.16% |
Jan. 30 | Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug | MT |
Jan. 30 | Nanobiotix: targets achieved for NANORAY-312 | CF |
- Stock
- Equities
- Stock Nanobiotix - Euronext Paris
- News Nanobiotix